Epizyme, Inc.









Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise



Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Market Cap: 2.43 Billion

Primary Exchange: NASDAQ


Shares Outstanding: 91.1 Million

Float: 76.4 Million

Dividend: (%)

Beta: 1.96214887103853

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 1675 trading days

From: 2013-07-16 To: 2020-01-17

Lowest Point:

Key events next week - healthcare

via: SeekingAlpha at 2019-06-13 03:28:10:000

Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...

Epizyme conference call on June 21 for tazemetostat

via: SeekingAlpha at 2019-06-12 03:57:07:000

Epizyme(NASDAQ: EPZM ) will host a conference call on June 21, at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. More news on: Epizyme, Inc., Read more … read more...

Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

via: Business Wire at 2019-06-12 02:30:00:000

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, taze… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud